Concluímos que o polimorfismo INDEL no gene TYMS é um importante biomarcador preditor de resposta a terapia com fluoropirimidinas. Os pacientes homozigotos selvagens (Ins/Ins) apresentaram uma proteção à progressão tumoral de 24% comparado com outros genótipos destes polimorfismos. Este achado corrobora com as recomendações de agências especializadas em oncologia mundiais que utilizam o marcador molecular INDEL no gene TYMS na pratica clínica.
Nesta investigação foi possível estabelecer uma correlação inversa entre o aumento da ancestralidade ameríndia e o desenvolvimento de metástase.
O presente estudo contribui no estabelecimento de bases metodológicas e cientificas para o desenvolvimento da medicina personalizada.
REFERÊNCIAS
ABRAHAM, J. et al. Pharmacogenetics of cancer chemotherapy. Biochimica et Biophysica Acta, v. 1766, n. 2, p. 168-83, 2006.
AGÊNCIA NACIONAL DE VIGILÂNCIA (ANVISA). Definições em Pesquisa Clínica. Disponível em: <http://www.anvisa.gov.br>. Acesso em: 14 jun. 2012.
AJANI, J. A. et al. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol., v. 23, n. 28, p. 6957-65, 2005.
AMSTUTZ, U. et al. Research article Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity : a haplotype assessment. Pharmacogenomics, v. 10, n. 6, p. 931-44, Jun. 2009.
ANDREASSI, M. G. et al. Genetic polymorphisms in XRCC1, OGG1, APE1 and XRCC3 DNA repair genes, ionizing radiation exposure and chromosomal DNA damage in
interventional cardiologists. Mutation Research/Fundamental and Molecular Mechanisms of mutagenesis, v. 666, n. 1-2, p. 57-63, Jun. 2009.
ARIYOSHI, N.; SAWAMURA, Y.; KAMATAKI, T. A novel single nucleotide
polymorphism altering stability and activity of CYP2a6. Biochem Biophys Res Commun., v. 281, n. 3, p. 810-4, Mar. 2001.
BAKER, S. D. et al. Phase I and pharmacological study of oral 5-fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil, J Clin Oncol., v. 18, n. 4, p. 915-26, Feb. 2000.
BASTOS-RODRIGUES, L.; PIMENTA, J. R.; PENA, S. D. J. The Genetic Structure of Human Populations Studied Through Short Insertion-Deletion Polymorphisms. Ann Hum Genetics, v. 70, pt. 5, p. 658-5, 2006.
BENDER, C. Implicações da quimioterapia para a enfermagem. In: CLARK, J. C.; Mc GEE, R. F. Enfermagem oncológica: um currículo básico. Porto Alegre: Artes Médicas, 1997. p. 325-35.
BENDER, C. Implicações da quimioterapia para a enfermagem. In: Enfermagem Oncológica: um currículo básico. Porto Alegre: Artes Médicas, 1997. p. 325-35.
BENHAMOU, S.; SARASIN, A. ERCC2 /XPD gene polymorphisms and lung cancer: a HuGE review. Am J Epidemiol., v. 161, n. 1, p. 1-14, 2005.
BENHAMOU, S.; SARASIN, A. ERCC2/XPD gene polymorphisms and cancer risk. Mutagenesis, v. 17, n. 6, p. 463-9, 2002.
BERGER, S. H.; HAKALA, M. T Relationship of dUMP and FdUMP pools to inhibition of thymidylate synthase by 5-fluorouracil. Mol Pharmacol., v. 25, n. 2, p. 303-9, Mar. 1984. BISHOP, D. K. et al. XRCC3 is required for assembly of Rad51 complexes in vivo. J Biol Chem., v. 273, n. 34, p. 21482-8, Aug. 1998.
BRASIL. Ministério da Saúde. Manual de bases técnicas da oncologia – SIA/SUS: Sistema de Informações Ambulatoriais. Brasília, DF: MS. 2011. p. 110.
BRASIL. Resolução RDC número 39, 05 de junho de 2008. Brasília, DF: Diário Oficial da União, 2008. (Seção 1: 106).
BRENNEMAN, M. A. et al. XRCC3 is required for efficient repair of chromosome breaks by homologous recombination. Mutat Res., v. 459, n. 2, p. 89-97, Mar. 2000.
BURSTEIN, H. J. et al. Trastuzumab and vinorelbine as first-line therapy for HER2- overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol., v. 21, n. 15, p. 2889-95, Aug. 2003.
CALLEGARI-JACQUES, S. M. et al. Historical Genetics: Spatiotemporal Analysis of the Formation of the Brazilian Population. Am J Hum Biol., v. 15, n. 6, p. 824-34, Nov./Dec. 2003.
CHOI, Y. J. et al. Biophysical characterization of the interaction domains and mapping of the contact residues in the XPF-ERCC1 complex. J Biol Chem., v. 280, n. 31, p. 28644-52, Aug. 2005.
CORNETTA, T. et al. DNA damage repair and genetic polymorphisms: assessment of individual sensitivity and repair capacity. Int J Radiat Oncol Biol Phys., v. 22, n. 2, p. 537- 45, Oct. 2006.
CRAIG, C. R.; STITZEL, R. E. Farmacologia moderna com aplicações clínicas. 6. ed. Rio de Janeiro: Guanabara Koogan, 2005.
CUSTÓDIO, A.; CALLES, A.; PÉREZ-SEGURA, P. Response to erlotininib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN. Clin Transl Oncol., v. 12, n. 4, p. 310-4, Apr. 2010.
DAAR, S. A.; SINGER, P. A. Pharmacogenetics and geographical ancestry: implications for drug development and global health. Nat Rev Genet., v. 6, n. 3, p. 241-6, Mar. 2005.
DABHOLKAR, M. et al. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest., v. 94, n. 2, p. 703-8, Aug. 1994.
DAIGO, S. et al. A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur. Pharmacogenetics, v. 12, n. 4, p. 299-306, Jun. 2002.
DANESI, R. et al. Pharmacogenetics in oncology. Eur J Clin Pharmacol., v. 6, p. 74-8, 2008.
DAVIES, S. M. et al. Glutathione S-transferase polymorphisms and outcome of
DEVITA, V. T.; CHU, E. A history of cancer chemotherapy. Cancer Res., v. 68, n. 21, p. 8643-53, 2008.
DIASIO, R. B. Clinical implications of dihydropyrimidine dehydrogenase on 5-FU pharmacology. Oncology, v. 15, n. 1, p. 21-6, Jan. 2001. Supplement.
DIASIO, R. B.; HARRIS, B. E. Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet., v. 16, p. 215-37, 1989.
DUSHINSKY, R.; PLEVEN, E.; HEIDELBERGER, C. The synthesis of 5- fluoropyrimidines. J Am Chem Soc., v. 79, n. 16, p. 4559-60, 1957.
EVANS, W. E.; JOHNSON, J. A. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Ann Rev Genomics Hum Genet., v. 2. p. 9-39, 2001.
EZER, R. et al. Identification of glutathione S-transferase (GST) polymorphism in brain tumors and association with susceptibility to pediatric astrocytomas. J of Neuro-Oncology., v. 59, p. 123-34, 2002.
EZZELDIN, H.; DIASIO, R. B. Dihydropyrimidine dehydrogenase deficiency, a
pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5- fluorouracil administration. Clin Colorectal Cancer, v. 4, p. 181-9, 2004.
FEJERMAN, L. et al. Genetic ancestraly and risk of mortality among U.S Latinas with breast cancer. Am Association Cancer Res., p. 7243-53, 2013.
FERNANDEZ-SALGUERO, P. et al. A genetic polymorphism in coumarin 7-
hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am J Hum Genet., v. 57, p. 651-60, 1995.
FIEGENBAUM, M.; HUTZ, M. H. Pharmacogenetic of lipid-lowering drugs. In: SIMPÓSIO FARMACOGENÉTICA, 39., 2006, p. 543-53.
FUJITA, K. Cytochrome P450 and anticancer drugs. Curr Drug Metab., v. 7, p. 23-37, 2006.
GODAI, T. et al. Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy. BMC Cancer, v. 9, p. 420, 2009.
GOODMAN, L. S. et al. Nitrogen mustard therapy: use of methyl-bis (h-chloroethyl) amine hydrochloride and tris (hchloroethyl) amine hydrochloride for Hodgkin’s disease,
lymphosarcoma, leukemia, and certain allied and miscellaneous disorders. JAMA, v. 132, p. 126-32, 1946.
GOSH, S. et al. Analysis of polymorphisms and haplotype structure of the human
thymidylate synthase genetic region: a tool for Pharmacogenetic studies. PLoS ONE, 2012. Disponível em:
<http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0034426>. Acesso em 21 nov. 2013.
GOTO, Y. et al. A novel single-nucleotide polymorphism in the 3′ untranslated region of the human dihydrofolate reductase gene with enhanced expression. Clin Cancer Res., v. 7, p. 1952-6, 2001.
GUSELLA, M. et al. Predictors of survival and toxicity in patients on adjuvant therapy with colorectal cancer. Br J Cancer, v. 100, n. 10, p. 1549-57, May 2009.
HANAHAN, D.; WEINBERG, R. A. Hallmarks of cancer: the next generation. Cell, v. 144, n. 5, p. 646-74, 2011.
HATA, T. et al. Mitomycin, a new antibiotic from Streptomyces. J Antib., v. 9, n. 4, p. 141- 6, 1956.
HOFF, P. M. et al. Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. Clin Cancer Res., v. 9, p. 134-42, 2003.
HOFFMAN, S. M. et al. Organization and evolution of the cytochrome P450 CYP2A-2B-2F subfamily gene cluster on human chromosome 19. J Mol Evol., v. 41, n. 6, p. 894-900, 1995.
HOLLSTEIN, M. et al. P53 mutations in human cancers. Science, v. 253, p. 49-53, 1991. HORIE, N. et al. Functional analysis and DNA poly- morphism of the tandemly repeated sequences in the 5'-terminal reg- ulatory region of the human gene for thymidylate synthase. Cell Struct Funct., v. 20, p. 191-7, 1995.
HOUTSMA, D.; GUCHELAR, H. J.; GELDERBLOM, H. Pharmacogenetics in oncology: a promising field. Curr Pharm Des., v. 16, n. 2, p. 155-63, 2010.
HUANG, S. M.; TEMPLE, R. Is this the drug or dose for you? Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice. Clin Pharmacol Ther., v. 84, p. 287-94, 2008.
HYAMA, T. et al. Genetic polymorphism and head and neck cancer risk (Review). Inter J Oncol., v. 32, p. 945-73, 2008.
IARMACOVAI, G. et al. Genetic Polymorphism and micronucleus formation: A review of the literature. Mutat Res., v. 658, n. 3, p. 215-33, Mar./Apr. 2008.
ICHIKAWA, W. et al. Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1. Int J Cancer, v. 119, n. 8, p. 1927-33, 2006.
IKEDA, K. et al. Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro. Clin Cancer Res, v. 6, p. 4409-15, 2000.
INNOCENTI, F.; RATAIN, M. J. Update on pharmacogenetics in cancer chemotherapy. Eur J Cancer, v. 38, p. 639-44, 2002.
INSTITUTO NACIONAL DO CÂNCER (INCA). 2012. Disponível em: <http://www.inca.gov.br>. Acesso em: 15 jul. 2012.
INSTITUTO NACIONAL DO CÂNCER (INCA). Estimativa 2012: incidência de câncer no Brasil. Rio de Janeiro: INCA, 2012. 118 p.
INSTITUTO NACIONAL DO CANCÊR JOSÉ ALENCAR GOMES DA SILVA. Estimativa 2014: incidência de câncer no Brasil. Rio de Janeiro: INCA, 2014.
JACOBSEN, N. R. et al. XRCC3 polymorphisms and risk of lung cancer. Cancer Lett., v. 213, p. 67-72, 2004.
JIAO, L. et al. XRCC2 and XRCC3 gene polymorphism and risk of pancreatic cancer. Am J Gastroenterol., v. 103, n. 2, p. 360-7, Feb. 2008.
JOHNSON, M. R. et al. Life-threatening toxicity in a dihydropy- rimidine dehydrogenase- deficient patient following treatment with topical 5-fluorouracil. Clin Cancer Res., v. 5, n. 8, p. 2006-11, 1999.
KANEDA, S. Structural and functional analysis of the human thymidylate synthase gene. J Biol Chem., v. 265, p. 20277-84, 1990.
KARRAN, P. DNA double strand break repair in mammalian cells. Curr Opin Genet Dev., v. 10, p. 144-50, 2000.
KAWAHARA, M. et al. Phase II study of S-1, a novel oral fluorouracil, in advanced non- small-cell lung cancer. Br J Cancer, v. 85, p. 939-43, 2001.
KITAJIMA, M. et al. The relationship between 5-fluorouracil sensitivity and single nucleotide polymorphisms of the orotate phosphoribosyl transferase gene in colorectal cancer. Oncol Rep., v. 15, n. 1, p. 161-5, 2006.
KIYOTANI, K. et al. Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6* 9). Pharmacogenetics, v. 13, p. 689-95, 2003.
KLOTZ, U. The role of pharmacogenetics in the metabolism of antiepileptic drugs:
pharmacokinetic and therapeutic implications. Clin Pharmacokinet, v. 46, p. 271-9, 2007. KOBAYAKAWA, M.; KOJIMA, Y. Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies. OncoTargets and Therapy, v. 4, p. 193-201, 2011.
KOIZUMI, W. et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol., v. 9, n. 3, p. 215-21, 2008. LEICHMAN, C. G. et al. Quantitation of intratu- moral thymidylate synthase expression predicts for disseminated col- orectal cancer response and resistance to protracted-infusion fluo- rouracil and weekly leucovorin. J Clin Oncol., v. 15, p. 3223-9, 1997.
LI, J.; BLUTH, M. H. Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy. Pharmacogenomics Pers Med., v. 4, p. 11-33, 2011. LIOU, S. Y. et al. Economic burden of haematological adverse effects in cancer patients: a systematic review. Clin Drug Investig., v. 27, p. 381-96, 2007.
LIU, G. et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol., v. 15, p. 110-5, 1997.
LOH, M.; SOONG, R. Challenges and pitfalls in the introduction of pharmacogenetics for cancer. Ann Acad Med Singapore, v. 40, n. 8, p. 369-74, 2011.
LONGLEY, D. B. et al. 5-Fluorouracil: Mechanisms of Action and Clinical Strategies. Nat Rev Cancer, v. 3, n. 5, p. 330-8, 2003.
LU, S. et al. Glutathione S-transferase P1 Ile105Val polymorphism and breast cancer risk: a meta-analysis involving 34,658 subjects. Breast Cancer Research Treat., v. 125, n. 1, p. 253-9, 2011.
LU, Z.; ZHANG, T.; DIASIO, R. B. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res. v. 53, p. 5433-8, 1993.
MAEHARA, Y. S-1 in gastric cancer: a comprehensive review. Gastric Cancer, v. 6, n. 1, p. 2-8, 2003. Supplement.
MALAIYANDI, V. et al. Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol Psychiatry, v. 11, p. 400-9, 2006.
MANDOLA, M. V. et al. A novel single nucleotide polymor- phism within 5´ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters
transcriptional activity. Cancer Res., v. 63, p. 2898-904, 2003.
MANUGUERRA, M. et al. XRCC3 and XPD/ERCC2 Single Nucleotide Polymorphisms and the risk of cancer: A HuGE review. Am J Epidemiol., v. 164, p. 297-302, 2006. MARSH, S. Thymidylate syntase pharmacogenetics. Investigational New Drugs, v. 23, n. 6, p. 533-7, 2005.
MATTISON, L. K.; JOHNSON, M. R.; DIASIO, R. B. A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservation of functional domains and relevance to genetic polymorphisms. Pharmacogenetics, v. 12, p. 133-44, 2002.
MATULLO, G. et al. XRCC1, XRCC3, XPD gene polymorphism, smoking and (32) P- DNA adducts in a sample of healthy subjects. Carcinogenesis, v. 22, p. 1437-45, 2001. MCLEOD, H. L. et al. Nomenclature for human DPYD alleles. Pharmacogenetics, v. 8, p.
455-9, 1998.
MCLEOD, H. L. et al. Pharmacogenetic analysis of systemic toxicity and response after 5- fluorouracil (5FU)/CPT-11, 5FU/oxaliplatin (oxal), or CPT-11/oxal therapy for advanced colorectal cancer. Proc Am Assoc Clin Oncol., v. 22, p. 252, 2003.
MEINSMA, R. et al. Human polymorphism in drug metabolism: mutation in the
dihydropyrimidine dehydrogenase gene results in exon skipping and thymine uracilurea. DNA Cell Biol., v. 14, n. 1, p. 1-6, 1995.
METANALYSIS GROUP IN CANCER (1998). Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol., v. 16, n. 1, p. 301-8, 1998.
METZGER, R. et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination
cisplatin and fluorouracil chemotherapy. J Clin Oncol., v. 16, p. 309-16, 1998. MEYER, U. A. Pharmacogenetics: five decades of therapeutic lessons from genetic diversity. Nature, v. 5, p. 669-76, 2004.
MILANO, G.; MCLEOD, H. L. Can dihydropyrimidine dehydroge- nase impact 5- fluorouracil-based treatment? Eur J Cancer, v. 36, p. 37-42, 2000.
MILES, J. S. et al. Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity. Biochem J., v. 267, p. 365-71, 1990.
NAGASUBRAMANIAN, R.; INNOCENTI, F.; RATAIN, M. J. Pharmacogenetics in cancer treatment. Ann Rev Med., v. 54, p. 437-52, 2003.
NAKAJIMA, M. et al. Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther., v. 80, n. 3, p. 282-97, 2006.
NAKAJIMA, M. et al. Novel human CYP2A6 alleles confound gene deletion analysis. FEBS letters, v. 569, n. 1-3, p. 75-81, 2004.
NIEDERNHOFER, L. J. et al. The structure-specific endonuclease ERCC1-XPF is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Bio., v. 24, p. 5776-87, 2004.
NISHIMURA, R. et al. Thymidylate synthetase levels as a therapeutic and prognostic predictor in breast cancer. Anticancer Res., v. 19, p. 5621-6, 1999.
NISHIYAMA, M.; EGUCHI, H. Pharmacokinetics and pharmacogenomics in gastric cancer chemotherapy. Adv Drug Deliv Rev., v. 61, n. 5, p. 402-7, 2009.
NUNOYA, K. I. et al. A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5- dimethyl-2-(3-pyridyl) thiazolidin-4-one hydrochloride (SM-12502). Pharmacogenetics, v.
8, p. 239-49, 1998.
OSAWA, K. Gene polymorphisms and Chemotherapyin Non-small Cell Lung cancer. Chin J Loung Cancer, v. 12, p. 837-40, 2009.
PARRA, F. C. et al. Color and genomic ancestry in Brazilians. Genet., v. 100, p. 177-82, 2003.
PESTANA, J. M. O.; CASTRO, M. C. R.; PEREIRA, W. Pesquisa Clínica e Farmacovigilância. Prática Hospitalar, v. 8, n. 44, mar./abr. 2006.
POCOCK, S. J. Clinical trials: a practical approach. Chichester: Wiley, 1983. PRITCHARD, J. K.; ROSENBERG, N. A. Use of unlinked genetic markers to detect population stratification in association studies. Am J Hum Genet., v. 65, p. 220-8, 1999. PULLARKAT, S. et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-U chemotherapy. Pharmacogenomics J., v. 1, p. 65-70, 2001.
RAUNIO, H. et al. Immunochemical and catalytical studies on hepatic coumarin 7- hydroxylase in man, rat and mouse. Biochem Pharmacol., v. 37, p. 3889-95,1988. REIS, M. Farmacogenética aplicada ao câncer. Quimioterapia individualizada e especificidade molecular, v. 39, n. 4, p. 577-86, 2006.
RIDGE, S. A. et al. Dihydropyrimidine dehydrogenase pharmacogenetics in Cau- casian subjects. Br J Clin Pharmacol., v. 46, p. 151-6, 1998.
ROOS, A. I. D. et al. Genetic polymorphisms in GSTM1, P1, T1, and CYP2EI and the risk of adult brain tumors. Cancer Epidemiology, Biomarkers & Prevention, v. 12, p. 14-22, 2003.
RUTSUM, Y. M. et al. Thymidylate synthetase inhibitors in cancer therapy: direct and indirect inhibitors. J Clin Oncol., v. 15, p. 389-400, 1997.
RYBERG, D. et al. Genotypes of Glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer risk. Carcinogenesis, v. 18, n. 7, p. 1285-9, 1997. SADEE, W.; DAI, Z. Pharmacogenetics/genomics and personalized medicine. Hum Mol Genet., v. 14, R207-14, 2005.
SALZANO, F. M.; BORTOLINI, M. C. The evolution and genetics of Latin American populations. Cambrigdge, UK: Cambridge University, 2002.
SAMBROOK, J.; FRITSCH, E. F.; MANIATIS, T. Molecular cloning: a laboratory manual. 2. ed. New York: Cold Springer Harbor, 1989. 1626 p.
SANTOS, N. P. C. et al. Assessing individual interethnic admixture and population substructure using a 48 insertion-deletion ancestry informative markers panel. Human Mutation, v. 31, p. 184-90, 2010.
SAVVA-BORDALO, J. et al. Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in
gastrointestinal cancer patients. BMC Cancer, v. 10, p. 420, 2010.
SCHMIDT, M. J. Human Safety in clinical research. Applied Clinical Trials, p. 40-7, Jul. 2001.
SCHOEDEL, K. et al. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics, v. 14, n. 9, p. 615-26, 2004.
SHAHROKNI, A.; RAJBI, M. R.; SAIF, M. W. Toxicity and Efficacy of 5-Fluororacil and capecitabine in a patient whith TYMS gene polymorphism: A challenge or a dilemma? Clinical Colorecta Cancer, v. 8, p. 231-234, 2009.
SHIRASAKA, T. Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. Jap J Clin Oncol., v. 39, n. 1, p. 2-15, 2009. SHIRASAKA, T. et al. Antitumor activity of 1 M tegarur- 0.4 M 5-chloro-2,4- dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res., v. 56, p. 2602-6, 1996.
SHIRASAKA, T.; SHIMAMOTO, Y.; FUKUSHIMA, M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res., v. 53, p. 4004-9, 1993.
SHIROTA, Y. et al. ERCC1 and thimidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol., v. 19, p. 4298-304, 2001.
SINGH, M. et al. Association of genetic polymorphisms in glutathione S-transferases and susceptibility to head and neck cancer. Mutation Research., v. 638, p. 184-94, 2008.
SMITH, T. R. et al. Polymorphisms of XRCC1and XRCC3 genes and susceptibility to breast cancer. Cancer Letters., v. 190, p. 183-90, 2003.
SOUSSI, T.; BEROUD, C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer, v. 1, p. 233-40, 2001.
SPILKER, B. Guide to clinical trials. Philadelphia: Lippincolt Willians e Wilkins, 2000. STEARNS, V.; RAE, J. M. Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response. Expert Reviews in Molecular Medicine, v. 10, p. 34, 2008.
STERPONE, S.; COZZI, R. Influence of XRCC1 genetic polymorphisms on Ionizing Radiatiation-Induced DNA damage and Repair. Journal of Nucleic Acids, v. 2010, 2010. STEWART, B. W.; KLEIHUES, P. Cancer management. In: ______. World cancer report.
France: IARC Press, 2003. p. 271-301.
SUAREZ-KURTZ, G. et al. Self-reported skin color, genomic ancestry and the distribution GST polymorphisms. Pharmacogenetics and Genomics, v. 17, p. 765-71, 2007.
SUAREZ-KURTZ, G. Pharmacogenomics in admixed populations. Trends Pharmacol Sci., v. 26, n. 4, p. 196-201, 2005.
SUCHI, M. et al. Molecular cloning of the human UMP synthase gene and characterization of point mutations in two hereditary orotic aciduria families. Am J Hum Genet., v. 60, n. 3, p. 525-39, 1997.
SUH, Y.; VIJG, J. SNP discovery in associating genetic variation with human disease phenotypes. Mutant Res., v. 573, n. 1-2, p. 41-53, 2005.
SWEENEY, C. et al. Association between survival after treat- ment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. Cancer Res., v. 60, p. 5621-4, 2000. SYAMALA, V. S. et al. Influence of germline polymorphisms of GSTT1, GSTM1, and GSTP1 in familial versus sporadic breast cancer susceptibility and survival. Familial Cancer, v. 7, n. 3, p. 213-20, 2008.
TAYLOR, J. G. et al. Using genetic variation to study human disease. Trends Molecular Medicine, v. 7, n. 11, p. 507-512, 2001.
TEBBS, R. S. et al. Correction of chromosomal instability and sensitivy to diverse mutagens by a cloned cDNA of the XRCC3 DNA repair gene. Proceedings National Academy Science USA, v. 92, p. 6354-8, 1995.
TEW, K. D. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res., v. 54, p. 4313-20, 1994.
THACKER, J.; ZDZIEBICKA, M. Z. The XRCC genes: expanding roles in DNA double- strand break repair. DNA Repair, v. 3, p. 1081-90, 2004.
TUCHMAN, M. et al. Familial pyrimidinemia and pyrimidinuria associated with severe fluoro- uracil toxicity. N Engl J Med., v. 313, p. 245-9, 1985.
ULRICH, C. M.; ROBIEN, K.; MCLEOD, H. L. Cancer pharmacogenet- ics: polymorphisms, pathways and beyond. Nat Rev Cancer, v. 3, p. 912-20, 2003.
VAN GENNIP, A. H. et al. Inborn errors of pyrimidine degradation: clinical, biochemical and molecular aspects. J Inherit Metab Dis., v. 20, p. 203-13, 1997.
VAN KUILENBURG, A. B. et al. Beta-alanine and beta-aminoisobutyric acid levels in two siblings with dihydropyrimidinase deficiency. Nucleosides Nucleotides Nucleic Acids., v. 27, n. 6, p. 825-9, Jun. 2008.
VIANI, G. A. et al. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer, v. 7, p. 153, 2007.
WALTHERS, A. et al. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer, 9, n. 7, p. 489-96, 2009.
WAN, J.; SANCHEZ, D. D. Antioxidant enzyme induction: A new protective approach against the adverse effects of diesel exhaust particles. Inhalation Toxicology, v. 19, n. 1, p. 177-82, 2007.
WANG, L.; MCLEOD, H. L.; WEINSHILBOUM, R. M. Genomics and drug response. The New England Journal of Medicine, v. 364, n. 12, p. 1144-53, 2011.
WANG, N. et al. An investigation on the polymorphisms of two DNA repair genes and susceptibility to ESCC and GCA of high-incidence region in northern China. Molecular Biology Rep., v. 36, p. 357-64, 2009.
WARNECKE-EBERZ, U. et al. High specificity of quantitative excision repair cross- complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin Cancer Res., v. 10, p. 3794-9, 2004.
WATTERS, J. W.; MCLEOD, H. L. Cancer pharmacogenom- ics: current and future applications. Biochim Biophys Acta, v.1603, p. 99-111, 2003.
WEI, X. et al. Molecular basis of the human dihydropyrimidine dehydrogen- ase deficiency and 5-fluorouracil toxicity. J Clin Invest., v. 98, p. 610-5, 1996.
WEINSHILBOUM, R. M.; WANG, L. Pharmacogenetics and pharmacogenomics: devel- opment, science, and translation. Annu Rev Genomics Hum Genet., v. 7, p. 223-45, 2006. WEINSHILBOUM, R.; WANG, L. Pharmacogenomics: Bench to Bedside. Nature
Reviews, v. 3, p. 739-48, 2004.
WHIBLEY, C.; PHAROAH, P. D.; HOLLSTEIN, M. P53 polymorphisms: cancer implications. Nat Rev Cancer, v. 9, p. 95-107, 2009.
WILDING, C. S. et al. DNA repair gene polymorphisms in realtion to chromosome
aberration frequencies in retired radiation workers. Mutation Res., v. 570, p. 137-45, 2005. WINSEY, S. L. et al. A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer. Cancer Res., v. 60, p. 5612-6, 2000.
WOHLHUETER, R. M.; MCIVOR, R. S.; PLAGEMANN, P. G. Facilitated transport of uracil and 5-fluorouracil, and permeation of orotic acid into cultured mammalian cells. J Cell Physiol., v. 104, p. 309-19, 1980.
WORLD HEALTH ORGANIZATION (WHO). World Cancer Report 2008. Lyon: International Agency for Research on Cancer, 2009.
YAMANO, S.; TATSUNO, J.; GONZALEZ, F. J. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Bio-Chemistry, v. 29, p. 1322-9,
1990.
YOSHIDA, R. et al. Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzy- matic activity in vivo and in vitro. Clin Pharmacol Ther., v. 74, p. 69-76, 2003.